Skip to main navigation

Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

05 Oct 2020

SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma

PDF Version

22 Sep 2020

SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

PDF Version

21 Sep 2020

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

PDF Version

18 Sep 2020

SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

PDF Version

16 Sep 2020

SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients

PDF Version

14 Sep 2020

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

PDF Version

12 Aug 2020

SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

PDF Version

04 Aug 2020

SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

PDF Version

22 Jul 2020

SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors

PDF Version

22 Jun 2020

BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 41 - 50 of 85

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Who We Are
Focus Areas

Pipeline
Careers
- View Opportunities

Patients
Contact

Investors & Media

© 2022 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use